Treatment outcomes of patients with classic and AIDS-related Kaposi Sarcoma: a single-center real-world experience

Bryan Valcarcel-Valdivia, Daniel Enriquez-Vera, Luis Enrique Piedra, Alexis Holguín, Gabriel De la Cruz Ku

Research output: Contribution to journalArticlepeer-review


The recommended first-line chemotherapy agents for managing Kaposi sarcoma (KS) in high-income countries are expensive and often unavailable in developing nations such as Peru. Limited data exist on whether management practices in these countries affect patient outcomes. We assessed the real-world treatment approaches and outcomes of patients with KS in Peru. We retrospectively reviewed the medical records of patients with acquired immunodeficiency syndrome-related KS (AIDS-related KS; n = 95) and classic KS (CKS; n = 81) diagnosed at a tertiary center between 2000 and 2014 in Lima, Peru. We used the Kaplan–Meier method to estimate overall survival (OS) rates. The median follow-up was 64 months for AIDS-related KS and 88 months for CKS. The median age of patients with AIDS-related KS was 35 years (range 20–63 years) and 70 years (range 33–91 years) for those with CKS. Most individuals had an Eastern Cooperative Oncology Group performance status of ≥ 2 (AIDS-related KS 75%; CKS 85%). Seventy-six percent and 40% of individuals with AIDS-related KS and CKS, respectively, received systemic chemotherapy. The most common first-line drug was paclitaxel, with relatively optimal overall response rates (ORRs) for AIDS-related KS (n = 64/72, 89%; ORR 61%) and CKS (n = 24/32, 75%; ORR 50%). The 5-year OS rates were 71% in the AIDS-related KS cohort and 81% in the CKS cohort. The findings from this real-world study may inform clinical practices and highlight the need for increased access to effective treatments and clinical trials for patients with KS in Peru and other developing countries.

Original languageEnglish
Pages (from-to)5463-5471
Number of pages9
JournalClinical and Experimental Medicine
Issue number8
StatePublished - Dec 2023


  • AIDS-related Kaposi sarcoma
  • Cohort Studies
  • Kaposi
  • Non-AIDS-related Kaposi sarcoma
  • Real‐world evidence
  • Sarcoma
  • Survival Analysis


Dive into the research topics of 'Treatment outcomes of patients with classic and AIDS-related Kaposi Sarcoma: a single-center real-world experience'. Together they form a unique fingerprint.

Cite this